atrial fibrillation
DISEASE INTERVENTION COMPARISON RESULTS
Circulation. 2002 Jul 16;106(3):331-6 Randomized Controlled Trial
IN atrial fibrillation, persistent The Use of
angiotensin II receptor blockers (irbesartan), added to amiodarone
As Treatment, Chronic
Is better Than
amiodarone alone
To reduce, at 9 months, recurrence of AF: 20% ibersartan plus VS 44% amiodarone alone
J Card Fail. 2007 Jun;13(5):340-5. Controlled Trial (non-randomized)
IN antiarrthythmic drugs, amiodarone, adverse effects, mortality, atrial fibrillation, heart failure The Use of
amiodarone
As Treatment, Chronic
Is worse Than
no amiodarone
To mortality: risk of death due to circulatory failure with amiodarone: HR 1.5
Mayo Clin Proc. 2009 Mar;84(3):234-42 Meta-Analysis
IN antiarrthythmic drugs, amiodarone, clinical use, adverse effects, atrial fibrillation, persistent, rhythm control strategy The Use of
amiodarone, low dose, 100 to 200 mg/d
As Treatment, Chronic
Is better Than
placebo
To restore and keep sinus rhythm (21.3% amiodarone vs 9.2% placebo at 1 year) but increase withdrawals by side effects (10.7% per year amiodarone vs 1.9% placebo)
Circulation. 2006 Aug 15;114(7):e257-354 Consensus, Guideline
IN atrial fibrillation The Use of
consensus guidelines
As -
Is useful Than
no comparison here
To guide diagnostic and therapeutic treatment of atrial fibrillation
J Am Coll Cardiol. 2005 Jun 7;45(11):1832-9 Meta-Analysis
IN atrial fibrillation The Use of
angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers
As Prevention, Primary
Is better Than
placebo
To reduce the incidence of new onset atrial fibrillation (most cumulated studies: RRR of 28%) and reduce its recurrence after conversion (2 studies)
N Engl J Med. 2011 Mar 10;364(10):928-38 Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation The Use of
angiotensin II receptor blockers, irbesartan
As Treatment, Chronic
Is equal Than
placebo
To reduce at 4 years cardiovascular events (stroke, myocardial infarction, or death): 5.4% per years in both groups. Neither it reduced AF recurrences in patients in sinus rhythm at baseline
J Fam Pract. 2000 Jan;49(1):47-59 Systematic Review
IN atrial fibrillation The Use of
calcium-channel blockers verapamil or diltiazem, beta-blockers, digoxin
As Treatment, Chronic
Is better Than
placebo
To adequately control heart rate. Verapamil, diltiazem and beta-blockers controlled better heart rate during exercise than digoxine.
Ann Intern Med 1999 Apr 20;130(8):625-36 Cost-Effectiveness
IN atrial fibrillation The Use of
cardioversion alone followed by repeated cardioversion plus amiodarone therapy on relapse
As Treatment, Chronic
Is better Than
cardioversion alone followed by warfarin therapy on relapse
To gain expected costs per quality-adjusted life-year (QALY). In the lowest-risk of stroke cohort, cardioversion alone followed by aspirin therapy on relapse was optimal.
Arch Intern Med 1998 Aug 10-24;158(15):1669-77 Cost-Effectiveness
IN atrial fibrillation The Use of
cardioversion followed by the use of aspirin alone or with amiodarone
As Treatment, Chronic
Is better Than
cardioversion followed by the use of amiodarone and warfarin
To gain expected costs per quality-adjusted life-year (QALY), but marginally, and cardioversion followed by amiodarone and warfarin resulted in the greatest gain in QALYs
Eur Heart J. 2016 Oct 07;37(38):2893-2962 Consensus, Guideline
IN atrial fibrillation The Use of
consensus guidelines
As Treatment, Chronic
Is useful Than
-
To guide diagnostic and therapeutics of atrial fibrillation
National Clinical Guideline Centre (UK). Guidance: The Management of Atrial Fibrillation Consensus, Guideline
IN atrial fibrillation The Use of
consensus guidelines
As Treatment, Chronic
Is better Than
no guidelines
To guide diagnostic and therapeutic treatment of atrial fibrillation
Am J Cardiol. 2003 Mar 20;91(6A):15D-26D Review (Narrative)
IN atrial fibrillation The Use of
diverse antiarrhythmic drugs
As Treatment, Chronic
Is useful Than
diverse other antiarrhythmic drugs
To not quantifiable outcomes here
Eur Heart J. 2010 Oct;31(19):2369-429 Consensus, Guideline
IN atrial fibrillation The Use of
consensus guidelines
As Undefined
Is useful Than
no comparison here
To guide diagnostic and therapeutics of atrial fibrillation
Drugs Aging. 2011 Aug 1;28(8):617-33 Review (Narrative)
IN atrial fibrillation, antiarrthythmic drugs, pharmacology, elderly patients The Use of
most of antiarrhythmic drugs
As Dosage Scheme
Is - Than
with respect to younger patietns
To a reduced dose of most antiarrhythmics should be employed in elder patients (20 to 40% reduction)
Stroke. 2009 Apr;40(4):1410-6 Meta-Analysis
IN atrial fibrillation, anticoagulants, vitamin K antagonists, bleeding risk, elder patients, stroke, ischemic, cerebral infarction, embolic The Use of
age
As Etiologic risk factor
Is useful Than
-
To predict an increased risk of stroke (HR per decade 1.45), major bleeding (HR per decade 1.61) and cardiovascular events (HR per decade 1.45). However the relative benefit of warfarin for preventing stroke persisted, while that of aspirin decreased
Value Health. 2000 Nov-Dec;3(6):407-16 Cost-Effectiveness
IN atrial fibrillation, cost The Use of
different treatment with drugs
As Treatment, Chronic
Is equal Than
each other
To reduce cost: no strategy was better. AF has high demands on medical resources, mainly because its complications and comorbidity.
Arch Intern Med. 1999 Apr 12;159(7):677-85 Decision Model
IN atrial fibrillation, elderly patients The Use of
warfarin
As Treatment, Chronic
Is better Than
aspirin or no treatment
To increase, in patients with average risk of stroke, expected QALYs: 12.9 warfarin, 11.2 aspirin and 10.15 no Tt.
J Am Geriatr Soc. 2002 May;50(5):863-9 Decision Model
IN atrial fibrillation, elderly patients The Use of
warfarin, anticoagulants
As Treatment, Chronic
Is equal Than
aspirin or no treatment
To increase expected QALYs: no compelling evidence of gain in quality-adjusted life expectancy with anticoagulation.
Lancet. 2007 Aug 11;370(9586):493-503 Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation, elderly patients, not high haemorrahgic risk, noT high stroke risk, anticoagulants, vitamin K antagonists, bleeding risk, elder patients The Use of
vitamin K antagonists, warfarin
As Treatment, Chronic
Is better Than
aspirin
To reduce all-type strokes: 1.8% warfarin versus 3.8% aspirin. No increase at all in major haemorrhages.
Lancet. 2000 Mar 18;355(9208):956-62 Decision Model
IN atrial fibrillation, embolic complications The Use of
vitamin K antagonists, warfarin
As Treatment, Chronic
Is better Than
aspirin or placebo
To reduce stroke and parterial embolism for most patients, specially those older
Heart. 2008 Dec;94(12):1607-13 Meta-Analysis
IN atrial fibrillation, embolic complications, systemic non-cerebral embolism The Use of
vitamin K antagonists, warfarin
As Treatment, Chronic
Is better Than
placebo or antiplatelet agents, aspirin
To reduce systemic embolism: OR 0.5 VS aspirin, OR 0.7 VS placebo. Increased major bleeding: OR 3 VS placebo.
Eur Heart J. 2006 Apr;27(8):949-53. Epub 2006 Mar 9 Cohorts
IN atrial fibrillation, epidemiology The Use of
incidence and prevalence of this arrhythmia
As -
Is useful Than
no comparison here
To plan health interventions concerning this disease: high lifetime risk to develop AF.
Eur Heart J. 2005 Nov;26(22):2422-34. Epub 2005 Oct 4 Descriptive, Cross-Sectional Study
IN atrial fibrillation, epidemiology The Use of
knowing actual current AF management
As Treatment, Chronic
Is useful Than
no comparison here
To consider interventions to improve adherence to guidelines, extract hypothesis to test in future randomized controlled trials
Value Health. 2006 Sep-Oct;9(5):348-56 Descriptive
IN atrial fibrillation, epidemiology, cost The Use of
costs attributable to treating atrial fibrillation
As -
Is - Than
no comparison here
To represents a significant health-care burden
Heart. 2001 Nov;86(5):516-21 Cohorts
IN atrial fibrillation, general population, prevalence, incidence The Use of
general population prevalence and incidence
As Undefined
Is useful Than
no comparison here.
To population prevalence of AF was 6.5 cases/1000 examinations. Incidence of AF was 0.54 cases/1000 person years
Am J Cardiol. 2003 Mar 20;91(6A):2D-8D Review (Narrative)
IN atrial fibrillation, heart failure The Use of
incidence, prevalence, patophysiology
As -
Is useful Than
-
To Different factors create an environment in which HF predisposes to AF and AF exacerbates HF. Although therapeutic options for AF are varied, their effect on prognosis remains unknown.
N Engl J Med. 2004 Dec 2;351(23):2373-83 Clinical Trial (non-controlled, non-randomized)
IN atrial fibrillation, heart failure, non-pharmacological treatment The Use of
catheter ablation, radiofrequency
As -
Is good Than
no relevant comparison group in this trial
To restore and maintain sinus rhythm: after 12 months 70% of patients maintained SR. Improve ejection fraction in those patients with heart failure (average of plus 20% at 12 months)
N Engl J Med. 2018 02 01;378(5):417-427 Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation, heart failure, systolic (reduced ejection fraction), non-pharmacological treatment The Use of
catheter ablation, radiofrequency
As Treatment, Acute
Is better Than
medical therapy (rate or rhythm control)
To reduce at 3 years a composite of all-cause death from or hospitalization for heart failure: 29% ablation VS 45% medical Tt. Significantly fewer patients in the ablation group died from any cause: 13% VS 25.0%
Circulation. 2007 Jun 19;115(24):3050-6 Cohorts
IN atrial fibrillation, lone The Use of
ageing, comorbidities and hypertension on the long term
As Prognostic Item
Is useful Than
-
To modulate progression and complications at 25 years: 31% developped permanent AF, stroke depended on associated risk factors, heart failure was increased, overall mortality was not increased.
J Am Coll Cardiol. 2007 Mar 6;49(9):986-92 Cohorts
IN atrial fibrillation, mortality The Use of
mortality, risk excess associated to AF
As Prognostic Item
Is useful Than
-
To know AF increases risk of death (HR 1,66 compared with general population), specially in the 4 months after diagnosis (HR 9.5)
Am J Med. 2007 Apr;120(4):357-63 Cohorts
IN atrial fibrillation, natural history The Use of
associated risks, first atrial fibrillation as risk marker
As Prognostic Item
Is useful Than
no comparison here
To predict risk of coronary event after diagnosis of AF: 31 per 1000 person-years, 17% at 6 years
N Engl J Med. 2009 Sep 17;361(12):1139-51. Epub 2009 Aug 30. Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation, non valvular, stroke, ischemic, cerebral infarction, embolic The Use of
oral direct thrombin inhibitors, dabigatran, 110 or 150 mg twice daily fixed dose
As Treatment, Chronic
Is better Than
warfarin, INR adjusted dose
To reduce at 2 years ischemic strokes (1.53% - 1.11% per year 110 - 150 mg dabigatran VS 1.69% warfarin), with similar major bleedings (2.71% - 3.36% per year) and less haemorrhagic strokes (0.10% per year dabigatran VS 0.38% warfarin)
Cochrane Database Syst Rev. 2007;(3):CD006186 Systematic Review, Cochrane Review
IN atrial fibrillation, non valvular, stroke, ischemic, cerebral infarction, embolic The Use of
vitamin K antagonists, warfarin
As Treatment, Chronic
Is better Than
aspirin
To reduce all stroke (OR 0.68) and systemic emboli (OR 0.48) but increasing intracranial haemorrhage (OR 1.98). No modification of mortality.
Cochrane Database Syst Rev. 2005 Jul 20;(3):CD001927 Systematic Review, Cochrane Review
IN atrial fibrillation, non valvular, stroke, ischemic, cerebral infarction, embolic The Use of
vitamin K antagonists, warfarin
As Treatment, Chronic
Is better Than
placebo or no treatment at all
To reduce all strokes (ARR 2.5% per year), reduce disabling or fatal stroke (ARR 1.2% per year) and reduce death (OR 0.69)
N Engl J Med. 2011 Feb 10. [Epub ahead of print] Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation, non valvular, stroke, ischemic, cerebral infarction, embolic, patients not suitable for vitamine K antagonists, warfarin The Use of
apixaban, oral factor Xa inhibitors
As Treatment, Chronic
Is better Than
aspirin
To reduce stroke or systemic embolism (1.6% per year apixaban VS 3.7% aspirin) while not increasing major bleeding (1.4% per year apixaban VS 1.2% aspirin)
Arch Intern Med. 2008 Mar 24;168(6):581-6 Systematic Review
IN atrial fibrillation, non-pharmacological treatment The Use of
catheter ablation, radiofrequency
As Treatment, Chronic
Is better Than
long-term antiarrhythmic drug therapy
To reduce at 1 year recurrence of AF (24.% abalation VS 81.2% antiarrhythmics) and reduce adverse events. No other clinical outcome assessed (mortality? heart failure?)
J Am Coll Cardiol. 2006 Jun 20;47(12):2513-20 Cost-Effectiveness
IN atrial fibrillation, non-pharmacological treatment The Use of
catheter ablation, radiofrequency
As Treatment, Chronic
Is better Than
other treatment strategies
To increase QALY at acceptable costs: ablation can be cost-effective in patients with moderate to high risk of stroke, but not at low risk.
Ann Intern Med. 2009 Aug 4;151(3):191-202. Epub 2009 Jul 6. Systematic Review
IN atrial fibrillation, non-pharmacological treatment The Use of
catheter ablation, radiofrequency, circumferential pulmonary vein ablation
As Treatment, Chronic
Is better Than
long-term antiarrhythmic drug therapy
To maintain sinus rhythm and possibly (lower strenght of evidence) improve quality of life, promote avoidance of anticoagulation, and decrease hospitalisation.
Ann Intern Med. 2009 Sep 1;151(5):297-305 Cohorts
IN atrial fibrillation, non-valvular The Use of
vitamin K antagonists, warfarin
As Treatment, Chronic
Is better Than
aspirin or no treatment
To obtain an average net clinical benefit of 0.68% per year, which was greater the higher the embolic risk was, icluding elderly patients
N Engl J Med. 2009 Apr 16;360(16):1606-17 Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation, paroxysmal The Use of
angiotensin II receptor blockers (ARB), valsartan
As Prevention, Secondary
Is equal Than
placebo
To reduce recurrences of AF: 51.4% valsartan VS 52% placebo.
Eur Heart J. 2006 Aug;27(15):1841-6 Randomized Controlled Trial
IN atrial fibrillation, paroxysmal The Use of
angiotensin converting enzyme (ACE) inhibitors (perindopril) or angiotensin II receptor blockers (losartan), added to amiodarone
As Treatment, Chronic
Is better Than
amiodarone alone
To reduce, at 2 years, recurrence of AF: 19% with sartan VS 24% with ACE inhibitor VS 41% amiodarone alone.
JAMA. 2005 Jun 1;293(21):2634-40 Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation, paroxysmal, non-pharmacological treatment The Use of
catheter ablation, radiofrequency
As Treatment, Chronic
Is better Than
chronic antiarrhythmic drug therapy
To reduce symptomatic AF recurrence (13% with ablation VS 63% with drugs) and hospitalizations (9% VS 54%). Pulmonary vein stenosis in 6% patients with ablation.
Am J Cardiol. 2012 Aug 15;110(4):607-13. doi: 10.1016/j.amjcard.2012.04.034. Epub 2012 May 19 Meta-Analysis
IN atrial fibrillation, paroxysmal, persistent, heart failure The Use of
dronedarone
As Treatment, Chronic
Is worse Than
placebo
To increase all-cause and cardiovascular mortality and increase heart failure exacerbations
N Engl J Med. 2009 Feb 12;360(7):668-78 Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation, paroxysmal, persistent, StudyID: ATHENA 2009 The Use of
dronedarone
As Treatment, Chronic
Is better Than
placebo
To reduce at 21 months cardiovascular deaths (2.7% dronedarone VS 3.9% placebo) and hospitalizations (26.9% dronedarone VS 33.4% placebo). No significant difference in overall mortality.
Circulation. 2009 Sep 29;120(13):1174-80 Randomized Controlled Trial
IN atrial fibrillation, paroxysmal, persistent, StudyID: ATHENA 2009, subordinated publication The Use of
dronedarone
As Treatment, Chronic
Is better Than
placebo
To reduce annual risk of stroke (all types): 1.2% dronedarone VS 1.8% placebo
Am Heart J. 2008 Jan;155(1):100-7, 107.e1 Randomized Controlled Trial
IN atrial fibrillation, paroxysmal, persistent, StudyID: PITAGORA 2008 The Use of
flecainide, or propafenone
As Treatment, Chronic
Is equal Than
amiodarone, sotalol
To modify, at 2 years, AF recurrence, mortality, adverse events
Int Heart J. 2008 May;49(3):281-93 Clinical Trial (non-controlled, non-randomized)
IN atrial fibrillation, paroxysmal, recurrent The Use of
beta-blockers, bisoprolol
As Treatment, Chronic
Is good Than
no comparison done
To improve symptoms and may be suppress recurrences (84% patients with diurnal AF had no recurrences?)
JAMA. 2008 Oct 15;300(15):1784-92 Randomized Controlled Trial
IN atrial fibrillation, paroxysmal, recurrent The Use of
continuous amiodarone, after electrical cardioversion
As Treatment, Chronic
Is better Than
amiodarone, episodic treatment, 1 month peri-electrical cardioversion
To reduce major events (either drug- or heart-related): 35% episodic VS 33% continouous amiodarone. All-cause mortality and cardiovascular hospitalizations were higher among those receiving episodic treatment (53% VS 34% continuous)
N Engl J Med. 2004 Dec 2;351(23):2384-91 Clinical Trial (non-controlled, non-randomized)
IN atrial fibrillation, paroxysmal, recurrent, mild or no cardiopathy The Use of
pill-in-the-pocket approach: self-administered oral loading of flecainide or propafenone
As Treatment, Chronic
Is useful Than
historical comparison
To reduce presumed AF recurrences, at 1.5 years (treatment successful in 84% of palpitations episodes), reducing emergency deparment visits, with 7% adverse events (1.5% severe)
J Am Coll Cardiol. 2006 Dec 5;48(11):2340-7 Randomized Controlled Trial
IN atrial fibrillation, paroxysmal, refractory, non-pharmacological treatment The Use of
catheter ablation, radiofrequency, circumferential pulmonary vein ablation
As Treatment, Chronic
Is better Than
change to another antiarrhythmic drug
To reduce, at 1 year, recurrences of AF: 7% with ablation VS 65% with drugs. Ablation was repeated in 9% patients and 2 severe adverse effects.
Circ Arrhythm Electrophysiol. 2011 Oct;4(5):637-43 Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation, paroxysmal, Study ID: Torp-Pedersen 2011 The Use of
vernakalant
As Treatment, Chronic
Is better Than
placebo
To reduce AF recurrence at 3 months, at the cost of several serious events associated (3 patients)
N Engl J Med. 2016 May 19;374(20):1911-21 Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation, paroxystic, after cardiac surgery, rate control strategy The Use of
rate control strategy
As Treatment, Chronic
Is equal Than
rhythm control strategy
To modify hospital stay, death, thromboembolic and bleeding events. At 60 days, 94% in rate control and 98% in rhythm control were in sinus rythm.
N Engl J Med. 2010 Apr 15;362(15):1363-73 Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation, permanent, rate control strategy The Use of
lenient rate control (resting heart rate <110 beats/min)
As Treatment, Chronic
Is equal Than
strict rate control (resting heart rate <80 beats/min and during moderate exercise <110 beats/min)
To modify at 2 years a composite of cardiovascular events: 12.9% lenient VS 14.9% strict (NS). Symptoms and adverse effects were also similar.
Eur Heart J. 2003 Dec;24(23):2090-8 Randomized Controlled Trial
IN atrial fibrillation, persistent The Use of
angiotensin converting enzyme (ACE) inhibitors, enalapril, added to amiodarone
As Treatment, Chronic
Is better Than
amiodarone alone
To increase number of patients in SR at at 8 months: 84.3% enalapril VS 61.3% amiodarone alone
J Am Coll Cardiol. 2004 Apr 7;43(7):1201-8 Randomized Controlled Trial
IN atrial fibrillation, persistent The Use of
beta-blockers, but with frequent changes and combination needed
As Treatment, Chronic
Is better Than
calcium-channel blockers, diltiazem, digoxin
To adequately control heart rate: 70% beta-blockers, 54% calcium-channel blockers, 58% digoxin.
Heart. 2008 Feb;94(2):191-6. Epub 2007 May 4 Cohorts
IN atrial fibrillation, persistent The Use of
digitalis, digoxin
As Treatment, Chronic
Is worse Than
other rate control drugs
To modify mortality: 6.5% digitalis VS 4.1% non-digitalis, HR 1.53 after adjustement for other risk factors
Ann Intern Med. 1994 Mar 15;120(6):449-57 Decision Model
IN atrial fibrillation, persistent The Use of
rhythm control using amiodarone
As Treatment, Chronic
Is better Than
some other strategies: no treatment, warfarin alone, rhythm control using quinidine
To gain more quality-adjusted life-years: amiodarone obtained the best value (4.75 years), followed by warfarin (4.72 years), quinidine (4.68 years), and no treatment (4.55 years).
J Am Coll Cardiol. 2005 Mar 1;45(5):705-11 Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation, persistent, hypertension, primary The Use of
angiotensin II receptor blockers (losartan)
As Treatment, Chronic
Is better Than
beta-blockers
To reduce cardiovascular events (composite of cardiovascular mortality, stroke, and myocardial infarction): 36/171 patients with losartan VS 67/171 patients with B-blokers, at aprox 4 years
JAMA. 2005 Feb 9;293(6):690-8 Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation, persistent, non valvular, stroke, ischemic, cerebral infarction, embolic The Use of
anticoagulants, direct thrombin inhibitors, ximelagatran
As Treatment, Chronic
Is equal Than
warfarin
To prevent, at 20 months, stroke (of any type): 1.6% xime. VS 1.2% warf. Elevated liver enzymes (>3N): 6% xime. VS 0.8% warf. Major and minor bleeding combined fewer with xime. (37%) than warf. (47%) but not major bleeding alone.
N Engl J Med. 2006 Mar 2;354(9):934-41 Randomized Controlled Trial
IN atrial fibrillation, persistent, non-pharmacological treatment The Use of
catheter ablation, radiofrequency
As Treatment, Acute
Is better Than
cardioversion and chronic amiodarone
To reduce atrial fibrillation recurrence: 26% with ablation VS 42% amiodarone; and improve symptoms. Complications: atypical atrial flutter.
Circulation. 2004 Mar 30;109(12):1509-13 Cohorts
IN atrial fibrillation, persistent, rate control strategy The Use of
warfarin use, recovering and maintaining sinus rhythm (either reciving rate or rhythm control management)
As Prognostic Item
Is better Than
not receiving warfaring or resting in atrial fibrillation
To predict a reduced mortality. However, no association of the administration of rate or rhythm control or antiarrhythmics with changes in mortality.
Ann Intern Med. 2004 Nov 2;141(9):653-61 Cost-Effectiveness
IN atrial fibrillation, persistent, rate control strategy The Use of
rate control strategy
As Treatment, Chronic
Is better Than
rhythm control strategy
To improve cost-effectiveness: rate control is always more effective and less costly
N Engl J Med. 2011 Dec 15;365(24):2268-76 Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation, persistent, rate control, pharmacologic, Study ID: PALLAS 2011 The Use of
dronedarone
As Treatment, Chronic
Is worse Than
placebo
To modify cardiovascular events: dronedarone increased deaths from cardiovascular causes (HR 2.1), stroke (HR 2.3) and heart failure (HR 1.8)
Lancet. 2012 Jul 21;380(9838):238-46 Randomized Controlled Trial
IN atrial fibrillation, persistent, StudyID: Flec-SL 2012 The Use of
flecainide
As Treatment, Chronic
Is better Than
no treatment
To reduce recurrences of AF at 4 weeks: 52% flecainide VS 70% no Tt. It seems the control group was not continued afterwards
Pharmacotherapy. 2007 Mar;27(3):360-8 Meta-Analysis
IN atrial fibrillation, postoperative, cardiac surgery The Use of
amiodarone, total doses > 3 grs, starting before or after surgery
As Prevention, Primary
Is better Than
placebo
To reduce the incidence of post-operative atrial fibrillation (OR 0.50)
Ann Intern Med. 2005 Sep 6;143(5):327-36 Meta-Analysis
IN atrial fibrillation, postoperative, cardiac surgery The Use of
antiarrhythmics, amiodarone
As Prevention, Primary
Is better Than
placebo
To decrease the incidence of atrial fibrillation or flutter (RR 0.64), ventricular arrhythmia (RR 0.42) and stroke (RR 0.39)
Eur Heart J. 2006 Jul;27(13):1584-91. Epub 2006 Jun 7 Randomized Controlled Trial
IN atrial fibrillation, postoperative, cardiac surgery The Use of
prophylaxis using antiarrhythmics, amiodarone, 600 mg oral single dose per day from Day-1 to Day7 plus IV perfusion during surgery
As Prevention, Primary
Is better Than
placebo
To reduce the incidence of post-operative AF: 34% with amiodarone VS 85% placebo. Also reduced hospitalization length of stay. Blood concentrations of amiodarone sig. differed between patients.
Cochrane Database Syst Rev. 2004 Oct 18;(4):CD003611 Systematic Review, Cochrane Review
IN atrial fibrillation, postoperative, cardiac surgery The Use of
several antiarrhythmics (amiodarone, sotalol, beta-blockers) and pacing
As Prevention, Primary
Is better Than
placebo
To reduce the incidence of atrial fibrillation (OR between 0.26 and 0.49) and possibly (non significant) reduces stroke and lenght of stay
Circulation. 2003 Sep 9;108 Suppl 1:II207-12 Cohorts
IN atrial fibrillation, postoperative, cardiac surgery The Use of
incidence, natural history
As Prognostic Item
Is useful Than
-
To the incidence of AF for the first year following CABG is higher in patients <70 years but not in those >70 years when compared with the general population. AF was associated to postoperative infection and renal dysfunction
Pacing Clin Electrophysiol. 2013 Jan;36(1):122-33 Meta-Analysis
IN atrial fibrillation, rate control strategy The Use of
rate control strategy
As Treatment, Chronic
Is equal Than
rhythm control strategy
To rate control carried fewer hospitalizations with no differences in mortality or other outcomes. In 5 studies with few patients (50 to 250, 650 patients total) conducted in patients <65 years old, rate control was associated with higher mortality
Arch Cardiovasc Dis. 2012 Apr;105(4):226-38 Meta-Analysis
IN atrial fibrillation, rate control strategy The Use of
rate control strategy
As Treatment, Chronic
Is equal Than
rhythm control strategy
To modify mortality, stroke, embolism or major bleeding
Br J Clin Pharmacol. 2005 Oct;60(4):347-54 Meta-Analysis
IN atrial fibrillation, rate control strategy The Use of
rate control strategy
As Treatment, Chronic
Is better Than
rhythm control strategy (cardioversion and antiarrhythmics)
To reduce adverse effects and hospitalizations. Complications of AF: death, ischaemic stroke and non-CNS bleeding were similar.
Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003713 Systematic Review, Cochrane Review
IN atrial fibrillation, rate control strategy The Use of
rate control strategy
As Treatment, Chronic
Is better Than
rhythm control strategy using pharmacologic cardioversion and antiarrhythmics
To reduce complications of AF: mortality was similar, rhythm control associated more adverse effects and hospitalisations
J Am Coll Cardiol. 2005 Nov 15;46(10):1891-9. Epub 2005 Oct 21 Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation, rate control strategy, functional status The Use of
rhythm control strategy (various antiarrhythmics)
As Treatment, Chronic
Is equal Than
rate control strategy
To modify functional status of patients: modest improvement in 6-min walk distance was noted in the rhythm-control arm (about 30m) no difference appeared in dyspnea, angor or cognitive function
Am J Med. 2006 May;119(5):448.e1-19 Systematic Review
IN atrial fibrillation, rate control strategy, functional status The Use of
rhythm control strategy (various antiarrhythmics)
As Treatment, Chronic
Is better Than
rate control strategy
To to improve quatily of life: 3 of 4 RCTs found a better improvement in QoL with rate control. Not compared patients in whom SR was restored with those in persistent AF.
Am J Med. 2013 Oct;126(10):887-93 Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation, rate control strategy, older patients The Use of
rate control strategy
As Treatment, Chronic
Is better Than
rhythm control strategy
To improve overall mortality at 3.4 years : 18% in rate control VS 23% in rhythm control
Ann Intern Med. 2014 Jun 03;160(11):760-73 Systematic Review
IN atrial fibrillation, rate control strategy, older patients with mild AF symptoms The Use of
rate control strategy
As Treatment, Chronic
Is equal Than
rhythm control strategy
To modify all cause mortality, cardiac mortality or stroke
Circulation. 2008 Mar 25;117(12):1518-25 Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation, recent onset The Use of
vernakalant
As Treatment, Acute
Is better Than
placebo
To acute, rapid cardioversion to sinus rhythm: 38 to 52 % vernakalant VS 3 to 4% placebo.
Crit Care Med. 2009 Jul;37(7):2174-9 Randomized Controlled Trial
IN atrial fibrillation, recent onset, acute, symptomatic The Use of
diltiazem, intravenous
As Treatment, Acute
Is better Than
digoxin, amiodarone, intravenous
To adequately control heart rate at 24 hours (90% diltiazem, 74% digoxine or amiodarone)
J Cardiovasc Electrophysiol. 2010 Jun 1;21(6):597-605 Study type to be defined
IN atrial fibrillation, recent-onset, persistent, StudyID: DYONISOS 2010 The Use of
dronedarone
As Treatment, Chronic
Is worse Than
amiodarone
To reduce, at 6 months, AF recurrence. Dronedarone had slightly fewer deaths and adverse events but differences were not significants
J Am Coll Cardiol. 2009 Sep 15;54(12):1089-95 Meta-Analysis
IN atrial fibrillation, recurrent The Use of
dronedarone
As Treatment, Chronic
Is worse Than
amiodarone, placebo
To prevent AF recurrences: OR 0.79 non-significant VS placebo, OR amiodarone VS dronedarone 0.49 significant) However, amiodarone had more withdrawals due to side effects (OR 1.81 significant)
Eur Heart J. 2006 Jan;27(2):216-21. Epub 2005 Oct 7 Randomized Controlled Trial
IN atrial fibrillation, refractory, non-pharmacological treatment The Use of
catheter ablation, radiofrequency AND and antiarrhythmic drugs (various)
As Treatment, Chronic
Is better Than
antiarrhythmic drug therapy alone (various drugs)
To prevent AF recurrence: 44% with ablation VS 91% without. Three (4.4%) major complications were related to ablation: stroke, pericardial effusion and a phrenic paralysis.
Arch Intern Med. 2006 Apr 10;166(7):719-28 Systematic Review
IN atrial fibrillation, rhythm control strategy The Use of
antiarrhythmic drugs, classes IA, IC, III
As Treatment, Chronic
Is worse Than
placebo or no treatment
To reduce mortality, class IA drugs (quinidine, dysopiramide) increased mortality (NNH 109) and the rest did not modify it. All drugs increased adverse effects and pro-arrhythmia (but amiodarone).
Cochrane Database Syst Rev. 2007;0(4):CD005049 Systematic Review, Cochrane Review
IN atrial fibrillation, rhythm control strategy The Use of
antiarrhythmic drugs, classes IA, IC, III
As Treatment, Chronic
Is worse Than
placebo or no treatment
To improve mortality: class IA drugs (quinidine, dysopiramide) increased mortality (NNH 109) and the rest did not modify it. All drugs increased adverse effects and pro-arrhythmia (but amiodarone).
JAMA. 2001 Jun 13;285(22):2864-70 Cohorts
IN atrial fibrillation, stroke, ischemic, cerebral infarction, embolic The Use of
CHADS2 score: 1 point each for heart failure, hypertension, age > 75 years, and diabetes mellitus and 2 points for history of stroke or TIA
As Prognostic Item
Is better Than
other scoring systems
To predict risk of stroke: stroke rate increased by 1.5% (95% CI, 1.3-1.7) for each 1-point increase in the CHADS( 2) score from 1.9% (95% CI, 1.2-3.0) for a score of 0.
Ann Intern Med. 2007 Jun 19;146(12):857-67 Systematic Review
IN atrial fibrillation, stroke, ischemic, cerebral infarction, embolic The Use of
vitamin K antagonists, warfarin
As Treatment, Chronic
Is better Than
aspirin
To reduce stroke (any type) rates: by 60% warfarin VS by 20% reduction with aspirin. Increases in major extracranial hemorrhage <= 0.3% per year)
JAMA. 2002 Nov 20;288(19):2441-8 Meta-Analysis
IN atrial fibrillation, stroke, ischemic, cerebral infarction, embolic The Use of
vitamin K antagonists, warfarin
As Treatment, Chronic
Is better Than
aspirin
To decrease stroke (of any type): 2.4% per year with warfarin VS. 4.5% with aspirin. But modestly increased major bleeding: 2.2 VS. 1.3% per year. Overall all-cause mortality did not differ
Arch Intern Med. 2005 May 23;165(10):1185-91 Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation, stroke, ischemic, cerebral infarction, embolic The Use of
vitamin K antagonists, warfarin
As Treatment, Chronic
Is better Than
aspirin or no treatment
To prevent stroke (69% relative risk decrease with warfarin)
Chest. 2010 Feb;137(2):263-72 Cohorts
IN atrial fibrillation, stroke, ischemic, cerebral infarction, embolic, peripheral embolism The Use of
CHA(2)DS2-VASc score: heart failure, hypertension, age≥75 years, diabetes, previous stroke/TIA, vascular disease, age 65-74 years, sex female. 1 point each, except age>75 & previous stroke, 2 points
As Prognostic Item
Is better Than
CHADS2 and other scores
To predict risk of stroke and peripheral embolism, at 1year, specially in patients at low risk: 0% if 0 points; 0,7% if 1 point; 1.9% if 2 points; 4.7% if 3 points. Less accuracy at scores 4,5 and 6, but fewer patients classified as "intermediate risk"
BMJ. 2011 Jan 31;342:d124. doi: 10.1136/bmj.d124 Cohorts
IN atrial fibrillation, stroke, ischemic, cerebral infarction, embolic, peripheral embolism The Use of
CHA(2)DS2-VASc score: heart failure, hypertension, age≥75 years, diabetes, previous stroke/TIA, vascular disease, age 65-74 years, sex female. 1 point each, except age>75 & previous stroke, 2 points
As Prognostic Item
Is better Than
CHADS2 score
To predict risk of stroke at 1year for patients at low risk: 0.78% if 0 points; 2% if 1 point
J Cardiovasc Electrophysiol. 2011 Jan;22(1):25-30 Cohorts
IN atrial fibrillation, stroke, ischemic, cerebral infarction, embolic, peripheral embolism, elder patients The Use of
CHADS2 and CHA(2)DS2-VASc scores
As Prognostic Item
Is better Than
other available scores
To predict risk of stroke and peripheral embolism: c-statistics 0.717 CHADS2 and 0.724 CHA(2)DS2-VASc. Patients categorized as "moderate-risk" were 5.3% with CHA(2)DS(2)-VASc and 49% with CHADS2
BMJ. 2011 Jun 23;342:d3653. doi: 10.1136/bmj.d3653 Cohorts
IN atrial fibrillation, stroke, ischemic, cerebral infarction, embolic, peripheral embolism, elder patients The Use of
CHADS2 and CHA(2)DS2-VASc scores
As Prognostic Item
Is equal Than
simple pragmatic rule classifying all patients > 75y as high risk
To all scores were similarly performant (c statistics 0.55-0.60). Moreover, they classified most patients as high risk (67% of patients) and the remaining as moderate risk
N Engl J Med. 2009 May 14;360(20):2066-78 Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation, stroke, ischemic, embolic The Use of
clopidogrel (75 mg/day) plus aspirin
As Treatment, Chronic
Is better Than
aspirin alone
To reduce major cardiovascular events, specially stroke (6.8% clopidogrel+aspirin VS 7.6% aspirin) but increased major haemorrhage (2% clopidogrel+aspirin VS 1.3% aspirin)
Zhonghua Yi Xue Za Zhi. 2006 Jan 10;86(2):121-3 Randomized Controlled Trial
IN atrial fibrillation, StudyID: Niu 2006 The Use of
amiodarone
As Treatment, Chronic
Is better Than
sotalol
To reduce, at 1 year, AF recurrence, with similar number of adverse events
J Am Coll Cardiol. 2005 Mar 1;45(5):712-9 Randomized Controlled Trial, Multicenter Study
IN hypertension, primary, ventricular hypertrophy, atrial fibrillation The Use of
angiotensin II receptor blockers (losartan)
As Treatment, Chronic
Is better Than
beta-blockers
To prevent development of new-onset atrial fibrillation: AF occurred in 6.8/1,000 person-years with losartan VS 10.1 with B-blockers.
Stroke. 1996 Oct;27(10):1760-4 Cohorts
IN stroke, ischemic, cerebral infarction, embolic, atrial fibrillation The Use of
being an embolic stroke due to atrial fibrillation
As Prognostic Item
Is worse Than
arterial stroke not associated to atrial fibrillation
To mortality was higher (25% vs 14% in patients without AF) and moderate to severe disability were more frequent when stroke was associated to AF.
Arch Intern Med. 2006 Jun 26;166(12):1269-75 Systematic Review
IN stroke, ischemic, cerebral infarction, embolic, atrial fibrillation The Use of
standard dose and low dose vitamin K antagonists, warfarin, ximelagatran, antiplatelet drugs, aspirin
As Treatment, Chronic
Is better Than
placebo
To prevent stroke (all types): standard-dose warfarin could prevent 28 ischemic strokes at the expense of 11 major bleedings, aspirin prevent 16 strokes with 6 major bleedings.
Am Heart J. 2002 Oct;144(4):597-607 Randomized Controlled Trial
IN Study ID: AF-CHF 2008 (subordinated publication), atrial fibrillation, rate control strategy, heart failure, chronic, systolic The Use of
rhythm control: electrical cardioversion combined with antiarrhythmic drugs (amiodarone or other class III agents)
As Treatment, Chronic
Is undefined Than
rate control
To primary end point : cardiovascular mortality (protocol for a RCT)
N Engl J Med. 2008 Jun 19;358(25):2667-77 Randomized Controlled Trial, Multicenter Study
IN Study ID: AF-CHF 2008, atrial fibrillation, rate control strategy, heart failure, chronic, systolic The Use of
rate control strategy
As Treatment, Chronic
Is equal Than
rhythm control strategy
To modify death from cardiovascular causes (25% rate-control VS 27% rhythm-control) or reduce stroke (4% rate-control VS 3% rhythm-control) or worsening heart failure (31% rate-control VS 28% rhythm-control)
Circ J. 2009 Feb;73(2):242-8 Randomized Controlled Trial
IN Study ID: J-RHYTHM 2009, atrial fibrillation, persistent, rate control strategy The Use of
rate control strategy
As Treatment, Chronic
Is equal Than
rhythm control
To modify mortality and cardiovascular morbidity at 1.5 years
Ann Intern Med. 2003 Dec 16;139(12):1009-17 Randomized Controlled Trial
IN StudyID: AAFP-ACP 2003, atrial fibrillation The Use of
any AAR (also review other recommendations of therapy)
As Treatment, Chronic
Is bad Than
-
To Most patients converted to sinus rhythm from atrial fibrillation should not be placed on rhythm maintenance therapy since the risks outweigh the benefits
Nord Med. 1968 Jun 13; 79(24): 781-2 Controlled Clinical Trial
IN StudyID: Aberg 1969 (subordinated publication), atrial fibrillation The Use of
procaine amide quinidine (?)
As Treatment, Chronic
Is not available Than
not available
To AF recurrence
Nord Med. 1969 Aug 14;82(33):1011-3 Controlled Clinical Trial
IN StudyID: Aberg 1969, atrial fibrillation The Use of
procaine amide quinidine (?)
As Treatment, Chronic
Is not available Than
not available
To not available
Am Heart J. 2006 May;151(5):1043-9 Randomized Controlled Trial
IN StudyID: A-COMET-I 2006, atrial fibrillation The Use of
azimilide
As Treatment, Chronic
Is equal Than
placebo
To maintain sinus rhythm or modify death at 6 months. Azimilide caused more adverse events and pro-arrhythmia
Eur Heart J. 2006 Sep;27(18):2224-31. Epub 2006 Aug 25 Randomized Controlled Trial
IN StudyID: A-COMET-II 2006, atrial fibrillation The Use of
azimilide, sotalol
As Treatment, Chronic
Is better Than
placebo
To prevent, at 6 months, AF recurrence without being stopped because adverse effects: sotalol 33% VS 19% azim VS 15% placebo. Both azimilide and sotalol increased proarrhythmia.
N Engl J Med. 2002 Dec 5;347(23):1825-33 Randomized Controlled Trial
IN StudyID: AFFIRM 2002, atrial fibrillation, rate control strategy The Use of
rate control strategy (drugs and anticoagulation)
As Treatment, Chronic
Is equal Than
rhythm control strategy (cardioversion and antiarrhythmics, anticoagulation recommended)
To overall mortality: 4,26%/year in rate-c vs 4,76%/year in rhythm-c. More patients in rhythm-c were hospitalized and suffered adverse drug effects
J Am Coll Cardiol. 2003 Jul 2;42(1):20-9 Randomized Controlled Trial
IN StudyID: AFFIRM Substudy 2003, atrial fibrillation, persistent The Use of
amiodarone
As Treatment, Chronic
Is better Than
sotalol, or a class I drug
To composite outcome (patients alive, in sinus rhythm, with no additional cardioversions and still taking the assigned drug) at 12 months: 60% amiodarone, 38% sotalol, 23% class I agents. Adverse effects were common.
Circulation. 1997 Oct 21;96(8):2625-32 Randomized Controlled Trial, Multicenter Trial
IN StudyID: AFIB 1997, atrial fibrillation The Use of
bidisomide
As Treatment, Chronic
Is equal Than
placebo
To AF recurrence, mortality - at ? Time
Am J Cardiol. 1996 Jan 25;77(3):66A-71A Randomized Controlled Trial
IN StudyID: Aliot 1996, atrial fibrillation, paroxysmal The Use of
flecainide
As Treatment, Chronic
Is equal Than
propafenone
To AF recurrence, proarrhythmia, adverse effects - at 12 months
Am J Cardiol. 1992;70(5):11A-17A Randomized Controlled Trial
IN StudyID: Anderson 1994 (subordinate publication), atrial fibrillation, rejected The Use of
flecainide
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects - at 4 months
Circulation. 1989 Dec; 80(6): 1557-70 Randomized Controlled Trial, Multicenter Trial
IN StudyID: Anderson 1994 (subordinate publication), atrial fibrillation, rejected The Use of
flecainide
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects - at 4 months
Am J Cardiol. 1994;74(6):578-84 Cross-Over
IN StudyID: Anderson 1994, atrial fibrillation, rejected The Use of
flecainide
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects - at 4 months
J Am Coll Cardiol. 1988 Oct;12(4):1005-11 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Antman 1990 (subordinated publication), atrial fibrillation The Use of
propafenone
As Treatment, Chronic
Is good Than
no comparison
To AF recurrence, adverse effects - at 6 months
J Am Coll Cardiol. 1990 Mar 1;15(3):698-707 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Antman 1990, atrial fibrillation The Use of
propafenone, sotalol if failure, sequentially
As Treatment, Chronic
Is good Than
no comparison
To AF recurrence, adverse effects - at 6 months
Rev Esp Cardiol. 1978;31(1 Pt 2):185-91 Randomized Controlled Trial
IN StudyID: Aros 1978, atrial fibrillation The Use of
quinidine plus amiodarone
As Treatment, Chronic
Is better Than
quinidine alone
To not available
Am J Cardiol. 2001 Nov 1;88(9):974-9 Randomized Controlled Trial
IN StudyID: ASAP 2003 (subordinated publication), atrial fibrillation The Use of
azimilide
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, pro-arrhythmia - at 6 months
Am Heart J. 2002 Apr;143(4):643-9 Randomized Controlled Trial
IN StudyID: ASAP 2003 (subordinated publication), atrial fibrillation The Use of
azimilide
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects - at 6 months
Am Heart J. 2003 Sep;146(3):489-93 Randomized Controlled Trial
IN StudyID: ASAP 2003 (subordinated publication), atrial fibrillation The Use of
azimilide
As Treatment, Chronic
Is better Than
placebo
To symptoms at AF recurrence, adverse effects - at 6 months
J Am Coll Cardiol. 2000 Sep;36(3):794-802 Randomized Controlled Trial
IN StudyID: ASAP 2003 (subordinated publication), atrial fibrillation The Use of
azimilide
As Treatment, Chronic
Is better Than
placebo
To AF recurrence - at ? Time
Circulation. 2003 Mar 4;107(8):1141-5 Randomized Controlled Trial
IN StudyID: ASAP 2003, atrial fibrillation The Use of
azimilide
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects - at 6 months
Am J Cardiol. 2006 Jul 15;98(2):215-8 Randomized Controlled Trial
IN StudyID: A-START 2006, atrial fibrillation, paroxysmal or recent-onset The Use of
azimilide
As Treatment, Chronic
Is equal Than
placebo
To modify time to AF recurrence. Azimilide increased adverse effects and pro-arrhytmia. No deats were reported
Ann Cardiol Angeiol (Paris). 1997 Feb;46(2):109-16 Randomized Controlled Trial, Multicenter Trial
IN StudyID: Babuty 1999 (subordinated publication), atrial fibrillation, paroxysmal The Use of
cibenzoline
As Treatment, Chronic
Is equal Than
flecainide
To AF recurrence, adverse effects, pro-arrhythmia - at 6 months
J Clin Pharmacol. 1995 May;35(5):471-7 Randomized Controlled Trial
IN StudyID: Babuty 1999 (subordinated publication), atrial fibrillation, paroxysmal The Use of
cibenzoline
As Treatment, Chronic
Is equal Than
flecainide
To AF recurrence, adverse effects, pro-arrhythmia - at 6 months
Annals of Noninvasive Electrocardiology. 1999;4(1):53-59 Randomized Controlled Trial
IN StudyID: Babuty 1999, atrial fibrillation, paroxysmal The Use of
cibenzoline
As Treatment, Chronic
Is equal Than
flecainide
To AF recurrence, adverse effects, pro-arrhythmia - at 6 months
Deutsche Medizinische Wochenschrift. 1978 Jun 30;103(26):1068-72 Randomized Controlled Trial
IN StudyID: Beck 1978, atrial fibrillation, persistent The Use of
propafenone
As Treatment, Acute
Is equal Than
lidoflazine
To acute conversion of AF
Curr Ther Res Clin Exp. 1995;56(11):1154-1168 Randomized Controlled Trial
IN StudyID: Bellandi 2001 (subordinated publication), atrial fibrillation, paroxysmal, recurrent The Use of
propafenone, sotalol
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse effects, proarrhythmia - at 12 months
Munchener Medizinische Wochenschrift. 1996;138 (12):39-46 Randomized Controlled Trial
IN StudyID: Bellandi 2001 (subordinated publication), atrial fibrillation, paroxysmal, recurrent The Use of
propafenone, sotalol
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse effects, proarrhythmia - at 12 months
Cardiology Review 2002;19(9):18-21 Randomized Controlled Trial
IN StudyID: Bellandi 2001 (subordinated publication), atrial fibrillation, paroxysmal, recurrent The Use of
propafenone, sotalol
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse effects, proarrhythmia - at 12 months
G Ital Cardiol. 1996 Apr;26(4):379-90 Randomized Controlled Trial
IN StudyID: Bellandi 2001 (subordinated publication), atrial fibrillation, paroxysmal, recurrent The Use of
propafenone, sotalol
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse effects, proarrhythmia - at 12 months
Am J Cardiol. 2001 Sep 15;88(6):640-5 Randomized Controlled Trial
IN StudyID: Bellandi 2001, atrial fibrillation, paroxysmal, recurrent The Use of
propafenone, sotalol
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse effects, proarrhythmia - at 12 months
Am J Cardiol. 1999 Aug 1;84(3):270-7 Randomized Controlled Trial, Multicenter Trial
IN StudyID: Benditt 1999, atrial fibrillation The Use of
sotalol
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, mortality, adverse effects - at 12 months
Circulation. 1998 Sep 8;98(10):946-52 Cohorts
IN StudyID: Benjamin 1998, atrial fibrillation, mortality The Use of
mortality, risk excess associated to AF
As Prognostic Item
Is useful Than
-
To AF was associated with an OR for death of 1.5 to 1.9 (men - women) after adjustment for several factors
Am J Cardiol. 1987 Jun 1;59(15):1337-41 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Berns 1987, atrial fibrillation, paroxysmal The Use of
flecainide
As Treatment, Chronic
Is good Than
no comparison
To AF recurrence, proarrhytmie, adverse effects - at 6 months
Arch Intern Med. 1987 Aug;147(8):1401-4 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Blevins 1987, atrial fibrillation, persistent, rejected The Use of
Amiodarone
As Treatment, Acute, Chronic
Is good Than
-
To AF recurrence, adverse effects, heart failure - at 16 Months
Acta Med Scand. 1984;216(5):517-24 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Blomstrom 1984, atrial fibrillation, rejected The Use of
amiodarone
As Treatment, Chronic
Is good Than
-
To AF recurrence, adverse effects, heart failure - at ? Months
Eur Heart J. 1981 Feb; 2(1): 49-55 not available
IN StudyID: Boissel 1981, atrial fibrillation The Use of
quinidine
As Treatment, Chronic
Is - Than
not available
To not available
Am J Cardiol. 1987 Sep 1;60(7):572-5 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Brodsky 1987, atrial fibrillation, persistent, rejected The Use of
Amiodarone
As Treatment, Chronic
Is good Than
-
To AF recurrence, adverse effects, heart failure - at 12 Months
Br Heart J 1970 May;32(3):370-6 Randomized Controlled Trial
IN StudyID: Byrne-Quinn 1970, atrial fibrillation The Use of
quinidine
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse effects, proarrhythmia, mortality - at 12 months
G Ital Cardiol. 1995 Jan;25(1):51-68 Randomized Controlled Trial
IN StudyID: Carunchio 1995, atrial fibrillation, paroxysmal The Use of
flecainide, sotalol
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adeverse effects - at 12 months
Eur Heart J. 2004 Jan;25(2):144-50 Randomized Controlled Trial
IN StudyID: Channer 2004, atrial fibrillation, persistent The Use of
amiodarone
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects - at 12 months
J Am Coll Cardiol. 2003 Jan 15;41(2):255-62 Meta-Analysis
IN StudyID: Chevalier 2003, atrial fibrillation The Use of
amiodarone
As Treatment, Acute
Is better Than
placebo
To converting AF to sinus rhythm. No difference in trials comparing againts class Ic drugs
Circulation. 1998 Dec 8;98(23):2574-9 Randomized Controlled Trial, Multicenter Trial
IN StudyID: CHF-STAT 1998, atrial fibrillation, heart failure The Use of
amiodarone
As Treatment, Chronic
Is better Than
placebo
To mortality, AF recurrence - at 12 months
Am J Cardiol. 1995 Jul 1;76(1):47-50 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Chun 1995, atrial fibrillation, paroxysmal, persistent The Use of
amiodarone
As Treatment, Chronic
Is good Than
no control group
To mortality, adverse effects, proarrhythmia, AF recurrence - at 12 months
Am J Cardiol. 1992 Aug 20;70(5):44A-49A Clinical Trial (non-controlled, non-randomized)
IN StudyID: Clementy 1992, atrial fibrillation, paroxysmal The Use of
flecainide
As Treatment, Chronic
Is - Than
no comparison
To mortality, AF recurrence, proarrhytmie, adverse effects - at 9 months
Am J Cardiol. 1989 Apr 1;63(12):817-9 Cross-Over
IN StudyID: Connolly 1989, atrial fibrillation, paroxysmal, recurrent The Use of
propafenone
As Treatment, Chronic
Is equal Than
placebo
To AF symptomatic recurrence
Am Heart J. 2000 May;139(5):752-60 Review (Narrative)
IN StudyID: Connolly 2000, atrial fibrillation The Use of
appropiate outcome measures: longer-term risks of stroke or death and patient quality of life
As -
Is better Than
just AF recurrences at ECG
To showing whether AF suppression reduces the longer-term risks of stroke or death and improves patient quality of life. AF recurrences that are symptomatic and therefore relevant to the patient also.
Circulation. 1990 Oct;82(4):1106-16 Meta-Analysis
IN StudyID: Coplen 1990, atrial fibrillation, pro-arrhythmia The Use of
quinidine
As Treatment, Chronic
Is worse Than
placebo
To overall unajusted mortality at 1 year: 2.9% in intv. vs 0.8% in cont. Patients remaining in sinus rhythm at 1 year were: 50% in intv. vs 24% in cont.
Eur Heart J. 2002 Jul;23(13):1050-6 Randomized Controlled Trial, Multicenter Trial
IN StudyID: CTAF 2000 (subordinated publication), atrial fibrillation The Use of
amiodarone
As Treatment, Chronic
Is better Than
sotalol, propafenone
To hospital and physician costs per patient - at 12 months
Am J Cardiol. 1997 Aug 15;80(4):464-8 Randomized Controlled Trial
IN StudyID: CTAF 2000 (subordinated publication), atrial fibrillation The Use of
amiodarone
As Treatment, Chronic
Is better Than
sotalol, propafenone
To AF recurrence, adverse effects, cost, quality of life - at 12 months
Am Heart J. 2002 Jun;143(6):984-90 Randomized Controlled Trial
IN StudyID: CTAF 2000 (subordinated publication), atrial fibrillation The Use of
amiodarone
As Treatment, Chronic
Is better Than
sotalol, propafenone
To improve quality of life - at 1 year
N Engl J Med. 2000 Mar 30;342(13):913-20 Randomized Controlled Trial
IN StudyID: CTAF 2000, atrial fibrillation The Use of
amiodarone, low dose
As Treatment, Chronic
Is better Than
sotalol, propafenone
To AF recurrence, adverse effects - at 12 months
Arch Inst Cardiol Mex. 1971 May-Jun; 41(3): 278-84 Not available
IN StudyID: Cuan-Perez 1971, atrial fibrillation The Use of
quinidine, diphenylhydantoin
As Treatment, Chronic
Is - Than
propranolol
To Not available
Eur Heart J. 2003 Aug;24(16):1481-7 Randomized Controlled Trial
IN StudyID: DAFNE 2003, atrial fibrillation, persistent The Use of
dronedarone
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects, pro-arrhythmia - at 6 months
Scand Cardiovasc J. 2003 Dec;37(6):324-8 Randomized Controlled Trial
IN StudyID: Dahlin 2003, atrial fibrillation, natural history, frequency of recidive The Use of
electrical cardioversion, not followed by antiarrhythmics
As Treatment, Chronic
Is bad Than
no control
To maintain sinus rhythm at long-term: only 13% of patients at 1 year
Am Heart J. 2008 Aug;156(2):373.e1-8 Randomized Controlled Trial
IN StudyID: DAPHNE 2008, atrial fibrillation, paroxysmal, sinus node disease The Use of
sotalol
As Treatment, Chronic
Is equal Than
beta-blockers, atenolol, metoprolol
To reduce AF recurrences
Arch Intern Med. 2005 Feb 14;165(3):258-62 Meta-Analysis
IN StudyID: Denus 2005, atrial fibrillation, rate control strategy The Use of
rate control strategy (drugs and anticoagulation)
As Treatment, Chronic
Is equal Than
rhythm control strategy (cardioversion and antiarrhythmics)
To reduce all-cause mortality: 14.6% rhythm-control vs 13.0% rate-control. A trend existed in favour of rate-control: OR 0.87; 95%CI 0.74-1.02
Ugeskr Laeger. 2000 Oct 30;162 (44);5948-53 Randomized Controlled Trial
IN StudyID: DIAMOND 2001 (subordinated publication), atrial fibrillation, persistent The Use of
dofetilide
As Treatment, Chronic
Is better Than
placebo
To mortality, FA recurrence, rehospitalization, heart failure - at 1 year
Congest Heart Fail. 2001 May-Jun;7(3):146-150 Randomized Controlled Trial, Multicenter Trial
IN StudyID: DIAMOND 2001 (subordinated publication), atrial fibrillation, persistent The Use of
dofetilide
As Treatment, Chronic
Is better Than
placebo
To mortality, FA recurrence, rehospitalization because heart failure, adverse effects, proarythmia - at 12 months
N Engl J Med. 1999 Sep 16;341(12):857-65 Randomized Controlled Trial, Multicenter Trial
IN StudyID: DIAMOND 2001 (subordinated publication), atrial fibrillation, persistent The Use of
dofetilide
As Treatment, Chronic
Is better Than
placebo
To mortality, FA recurrence, rehospitalization, heart failure - at 18 months
Circulation. 2001 Jul 17;104(3):292-6 Randomized Controlled Trial, Multicenter Trial
IN StudyID: DIAMOND 2001, atrial fibrillation, persistent The Use of
dofetilide
As Treatment, Chronic
Is better Than
placebo
To mortality, FA recurrence, rehospitalization, heart failure - at 12 months
Acta Cardiol. 2004 Jun;59(3):255-61 Randomized Controlled Trial
IN StudyID: Dogan 2004, atrial fibrillation The Use of
propafenone
As Treatment, Chronic
Is better Than
placebo
To at 15 months: AF recurrence, adverse effects
J Am Coll Cardiol. 2000 Feb;35(2 Suppl. A):154A-155A Randomized Controlled Trial
IN StudyID: EMERALD 1998 (subordinated publication), atrial fibrillation The Use of
dofetilide, sotalol
As Treatment, Chronic
Is undefined Than
placebo
To mortality at 1 year
Circulation. 1998 Oct 27;98(17):66 Suppl. 13-14 Randomized Controlled Trial
IN StudyID: EMERALD 1998 (subordinated publication), atrial fibrillation The Use of
dofetilide, sotalol
As Treatment, Chronic
Is undefined Than
placebo
To AF recurrence, adverse effects, pro-arrhythmia - at 6 months
Drugs. 1999 Dec;58(6):1043-59 Review (Narrative)
IN StudyID: EMERALD 1998 (subordinated publication), atrial fibrillation The Use of
dofetilide, sotalol
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects, pro-arrhythmia - at 6 months
Circulation. 1998 Oct 27;98(17):3326 Suppl. I-633 Randomized Controlled Trial
IN StudyID: EMERALD 1998 (subordinated publication), atrial fibrillation The Use of
dofetilide, sotalol
As Treatment, Chronic
Is undefined Than
placebo
To AF recurrence, adverse effects, pro-arrhythmia - at 6 months
Accessed 2010 August 10 at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20-931_Tikosyn.cfm Randomized Controlled Trial
IN StudyID: EMERALD 1998, atrial fibrillation The Use of
dofetilide, sotalol
As Treatment, Chronic
Is better Than
placebo
To reduce, at 1 year, AF recurrence. But they did not modified mortality and both increased adverse events and pro-arrhythmia
Am J Cardiol. 2002 Dec 15;90(12):1300-6 Randomized Controlled Trial, Multicenter Trial
IN StudyID: ERAFT 2002, atrial fibrillation, paroxysmal The Use of
propafenone
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse events - at what time?
N Engl J Med. 2007 Sep 6;357(10):987-99 Randomized Controlled Trial, Multicenter Study
IN StudyID: EURIDIS ADONIS 2004, atrial fibrillation The Use of
dronedarone
As Treatment, Chronic
Is better Than
placebo
To reduce at 1 year recurrence of AF (% of recurrences ?). Effect on mortality, stroke, heart failure ?
Minerva Med. 1970 Sep 5; 61(71 Suppl): 3745-7 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Faivre 1970, atrial fibrillation The Use of
disopyramide
As Treatment, Chronic
Is useful Than
retrospective series of different AA
To Not available
Eur Heart J. 1995 Dec;16(12):1943-51 Randomized Controlled Trial, Multicenter Trial
IN StudyID: FAPIS 1996 (subordinated publication), atrial fibrillation, paroxysmal The Use of
flecainide
As Treatment, Chronic
Is equal Than
propafenone
To AF recurrence, proarrhythmia, adverse effects - at 12 months
Am J Cardiol. 1996 Jan 25;77(3):60A-65A Randomized Controlled Trial, Multicenter Trial
IN StudyID: FAPIS 1996, atrial fibrillation, paroxysmal The Use of
flecainide
As Treatment, Chronic
Is equal Than
propafenone
To AF recurrence, proarrhythmia, adverse effects - at 12 months
Rev Esp Cardiol. 1998;51(Suppl 5):84 Randomized Controlled Trial
IN StudyID: Fernandez 1998, atrial fibrillation, paroxysmal The Use of
amiodarone, flecainide
As Treatment, Acute
Is - Than
propafenone
To acute revers atrial fibrillation to sinus rhythm
J Am Coll Cardiol. 1992 Sep;20(3):527-32 Randomized Controlled Trial
IN StudyID: Flaker 1992, atrial fibrillation, pro-arrhythmia The Use of
diverse antiarrhythmic drugs
As Treatment, Chronic
Is worse Than
no treatment
To overall mortality, specially in patients with heart failure
Am J Cardiol. 1995 Aug 15;76(5):355-8 Descriptive
IN StudyID: Flaker 1995, atrial fibrillation The Use of
risk factors for recurrence and persistence, clinical and echocardiography data
As Prognostic Item
Is useful Than
-
To Clinical factors predicting recurrent AF were age, heart failure, and myocardial infarction. At echocardiography, enlarged left atrium predicted recurrence of AF and enlarged left ventricle predicted conversion to constant AF.
Arch Mal Coeur Vaiss. 1985 Oct; 78 Spec No: 99-103 Randomized Controlled Trial
IN StudyID: Frances 1985, atrial fibrillation The Use of
cibenzoline
As Treatment, Chronic
Is equal Than
quinidine
To AF recurrences, adverse effects - at 6 months
Clin Cardiol. 2001 Mar;24(3):238-44 Descriptive
IN StudyID: Frick 2001, atrial fibrillation, persistent The Use of
elective electrical cardioversion
As Treatment, Acute
Is equal Than
no comparison here
To restore sinus rhythm in 75% patients. At 4 weeks only 37% of patients maintained sinus rhythm. Duration of AF < 3 months and right atrial dimension < 37 mm were independent predictors of maintaining SR
Am J Cardiol. 1998 Oct 16;82(8A):50N-58N Review (Narrative)
IN StudyID: Friedman 1998, atrial fibrillation, pro-arrhythmia definition The Use of
criteria to define proarrhythmia
As Diagnostic Tool
Is useful Than
-
To characterize toxicity of drugs
Am J Cardiol. 1994 Aug 1;74(3):236-41 Descriptive
IN StudyID: Furberg 1994, atrial fibrillation The Use of
aetiology: coexistence of clinical or subclinical cardiovascular disease, prevalence of AF
As -
Is - Than
-
To AF existed 4.8% of women and in 6.2% of men > 65 years. The observed low prevalence of AF in the absence of sub/clinical cardiovascular disease calls into question the existence of so-called "lone AF" in the elderly
J Cardiovasc Pharmacol Ther. 2003 Sep;8(3):179-86 Clinical Trial (non-controlled, non-randomized)
IN StudyID: GEFACA 2001 (subordinated publication), atrial fibrillation, persistent The Use of
amiodarone
As Treatment, Chronic
Is - Than
no comparison
To AF recurrence, adverse effects - at > 12 months
J Cardiovasc Pharmacol Ther. 2001 Oct;6(4):341-50 Randomized Controlled Trial, Multicenter Trial
IN StudyID: GEFACA 2001, atrial fibrillation, persistent The Use of
amiodarone
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects - at average 9 months
J Cardiol 2001 Feb;37(2):103-7 Descriptive
IN StudyID: Geleris 2001, atrial fibrillation, recent-onset The Use of
rate of spontaneous conversion to sinus rhythm
As Prognostic Item
Is - Than
-
To occurred in 71% of patients, mostly in first 12 hr. Left atrial size was the only predictor of spontaneous conversion. Age, gender, other clinical characteristics, left ventricular dimensions and performance did not predict.
JAMA 2001 May 9;285(18):2370-5 Descriptive, Cross-Sectional Study
IN StudyID: Go 2001, atrial fibrillation The Use of
prevalence, in an study population of 1.89 million at the USA
As -
Is useful Than
-
To planning health resources. The global prevalence of AF was 0.95%, it increased from 0.1% among adults < 55 years to 9.0% in those > 80 years
Am J Cardiol. 1986 Jan 1;57(1):124-7 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Gold 1986, atrial fibrillation, persistent, rejected The Use of
Amiodarone
As Treatment, Chronic
Is good Than
-
To AF recurrence, adverse effects, heart failure - at ? Months
Ann Intern Med 1996 Aug 15;125(4):311-23 Review (Narrative)
IN StudyID: Golzari 1996, atrial fibrillation, existing meta-analysis The Use of
diverse antiarrhythmic drugs
As Treatment, Chronic
Is better Than
no treatment
To restoring and maintaining sinus rhythm
JAMA. 1992 Jun 24; 267(24): 3289-93 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Gosselink 1992, atrial fibrillation, rejected The Use of
amiodarone
As Treatment, Chronic
Is useful Than
no controls
To AF recurrence, adverse effects - at 3 years
Am Heart J. 1983 Oct;106(4 Pt 2):870-6 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Graboys 1983, atrial fibrillation, paroxysmal, rejected The Use of
amiodarone
As Treatment, Chronic
Is good Than
-
To AF recurrence, adverse effects, heart failure - at 27,3 Months
Heart 2002 Oct;88(4):357-62 Randomized Controlled Trial
IN StudyID: GUSTO 2002, atrial fibrillation The Use of
class I agents, sotalol
As Treatment, Chronic
Is better Than
amiodarone, no treatment
To mortality at 30 days and 12 months
Am J Cardiol. 1988 Feb 15;61(6):473-4 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Hammil 1988, atrial fibrillation, persistent The Use of
propafenone
As unknow
Is - Than
unknow
To unknow
Die Medizinische Welt. 1969;20(25):1464 not available
IN StudyID: Hartel 1970 (subordinated publication), atrial fibrillation The Use of
quinidine
As Treatment, Chronic
Is not available Than
not available
To not available
Klinische Wochenschrift. 1969;47(17):942 not available
IN StudyID: Hartel 1970 (subordinated publication), atrial fibrillation The Use of
quinidine
As Treatment, Chronic
Is not available Than
not available
To not available
Br Heart J 1970 Jan;32(1):57-60 not available
IN StudyID: Hartel 1970, atrial fibrillation The Use of
quinidine
As Treatment, Chronic
Is - Than
not available
To not available
Clin Pharmacol Ther. 1974 Jun; 15(6): 551-5 Controlled Clinical Trial
IN StudyID: Hartel 1974, atrial fibrillation The Use of
disopyramide
As Treatment, Chronic
Is - Than
not available
To AF recurrence, not available
Br Heart J 1971 Jul;33(4):518-21 Controlled Clinical Trial
IN StudyID: Hillestad 1971, atrial fibrillation The Use of
quinidine
As Treatment, Chronic
Is better Than
no treatment
To recurrence of symptomatic arrhythmia, adverse effects, proarrhythmia, mortality - at 12 months
J Am Coll Cardiol. 1995 Oct;26(4):852-8 Randomized Controlled Trial
IN StudyID: Hohnloser 1995, atrial fibrillation, persistent The Use of
quinidine
As Treatment, Chronic
Is equal Than
sotalol
To AF recurrence, proarrhythmia, adverse effects - at 6 months
Am J Cardiol. 1996 Jan 25;77(3):72A-82A Clinical Trial (non-controlled, non-randomized)
IN StudyID: Hopson 1996 (former FSTS), atrial fibrillation, rejected The Use of
flecainide
As Treatment, Chronic
Is - Than
non controlled
To arrhytmia recurrence, pro-arrhytmia, adverse effects
J Am Coll Cardiol. 1985 Dec;6(6):1402-7 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Horowitz 1985, atrial fibrillation, persistent, rejected The Use of
amiodarone
As Treatment, Chronic
Is good Than
-
To AF recurrence, adverse effects - at 15 months
Kardiol Pol. 2003 Jul;59(7):1-16; discussion 15-16 Randomized Controlled Trial
IN StudyID: HOT-CAFE 2004 (subordinated publication), atrial fibrillation, persistent The Use of
various antiarrhythmics
As Treatment, Chronic
Is equal Than
rate control
To mortality, stroke, heart failure, AF recurrence, adverse effects - at 1 year
Pol Arch Med Wewn. 1999 May;101(5):413-8 Randomized Controlled Trial
IN StudyID: HOT-CAFE 2004 (subordinated publication), atrial fibrillation, persistent The Use of
various antiarrhythmics
As Treatment, Chronic
Is equal Than
rate control
To mortality, stroke, heart failure, AF recurrence, adverse effects - at 1 year
Chest. 2004 Aug;126(2):476-86 Randomized Controlled Trial, Multicenter Trial
IN StudyID: HOT-CAFE 2004, atrial fibrillation, persistent The Use of
various AA
As Treatment, Chronic
Is worse Than
rate control
To mortality, stroke, heart failure, AF recurrence, adverse effects - at 1 year
Circ J. 2009 Jun;73(6):1020-7 Randomized Controlled Trial
IN StudyID: J-BAF 2009, atrial fibrillation, persistent The Use of
bepridil
As Treatment, Chronic
Is worse Than
placebo
To modify outcomes at 3 months: higher cardioversion to SR with bepridil but high recurrence of AF and significant pro-arrhythmia
Circulation. 1990 Dec;82(6):1932-9 Randomized Controlled Trial
IN StudyID: Juul-Moller 1990, atrial fibrillation, persistent The Use of
sotalol
As Treatment, Chronic
Is equal Than
quinidine
To AF recurrence, adverse effects - at 6 months
Z Kardiol. 1994;83(5):109-116 Randomized Controlled Trial
IN StudyID: Kalusche 1994, atrial fibrillation, persistent The Use of
amiodarone
As Treatment, Chronic
Is equal Than
quinidine + verapamil
To
Am J Cardiol. 2004 Sep 1;94(5):659-62 Randomized Controlled Trial
IN StudyID: Kanoupakis 2004, atrial fibrillation, persistent The Use of
amiodarone
As Treatment, Chronic
Is good Than
no comparison
To AF recurrence, adverse effects - at 4 weeks
Lakartidningen. 1991 Jun 12;88(24):2242-5 Randomized Controlled Trial
IN StudyID: Karlson 1988 (subordinated publication), atrial fibrillation The Use of
disopyramide
As Treatment, Chronic
Is better Than
placebo
To not available
Eur Heart J. 1988 Mar;9(3):284-90 Randomized Controlled Trial
IN StudyID: Karlson 1988, atrial fibrillation The Use of
disopyramide
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse effects, stroke, mortality - at 12 months
Br Heart J. 1977;39(5):540-6 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Kenelly 1977, atrial fibrillation, persistent The Use of
lidoflazine
As Treatment, Chronic
Is worse Than
quinidine
To mortality: The trial was stopped after 4 patients died while receiving lidoflazine, probably by drug-induced arrhythmias
Am J Cardiol. 1988 Apr 15;61(11):914-6 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Kerr 1988, atrial fibrillation The Use of
propafenone
As Treatment, Chronic
Is - Than
not available
To not available
Chest. 2004 Feb;125(2):377-83 Randomized Controlled Trial
IN StudyID: Kochiadakis-AmPro 2004, atrial fibrillation The Use of
amiodarone, propafenone
As Treatment, Chronic
Is good Than
0
To AF recurrence, adverse effects - at 10 months
Am J Cardiol. 1998 Apr 15;81(8):995-8 Randomized Controlled Trial
IN StudyID: Kochiadakis-AmSot 2000 (subordinated publication DVD), atrial fibrillation The Use of
amiodarone
As Treatment, Chronic
Is better Than
sotalol
To AF recurrence, adverse effects - at 12 months
Pacing Clin Electrophysiol. 2000 Nov;23(11 Pt 2):1883-7 Randomized Controlled Trial
IN StudyID: Kochiadakis-AmSot 2000 (subordinated publication), atrial fibrillation The Use of
amiodarone, propafenone
As Treatment, Chronic
Is better Than
sotalol
To AF recurrence, adverse effects - at 6 to 16 months
Heart 2000 Sep;84(3):251-7 Randomized Controlled Trial
IN StudyID: Kochiadakis-AmSot 2000, atrial fibrillation The Use of
amiodarone, sotalol
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects - at 6 to 16 months
Am J Cardiol. 2004 Dec 15;94(12):1563-6 Randomized Controlled Trial
IN StudyID: Kochiadakis-ProSot 2004, atrial fibrillation The Use of
propafenone, sotalol
As Treatment, Chronic
Is better Than
placebo
To mortality, pro-arrhythmia, AF recurrence, adverse effects - at 18 to 25 months
Medical Science Monitor 2001 Jan-Feb;7(1):68-73 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Kosior 2002 (subordinated publication), atrial fibrillation, rejected The Use of
various AARs
As Treatment, Chronic
Is - Than
no control
To AF recurrence
Kardiol Pol. 2002;56(4):361-367 Randomized Controlled Trial
IN StudyID: Kosior 2002 (subordinated publication), atrial fibrillation, rejected The Use of
various AARs, sequential antiarrhythmic therapy
As Treatment, Chronic
Is better Than
no control
To AF recurrence - at 1 year
Pol Arch Med Wewn. 2002 Dec;108(6):1151-60 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Kosior 2002, atrial fibrillation, rejected The Use of
various AARs
As Treatment, Chronic
Is - Than
no control
To AF recurrence
Am J Med. 1995 May;98(5):476-84 Descriptive, propspective
IN StudyID: Krahn 1995, atrial fibrillation, natural history The Use of
incidence, aetiology, natural history: associated risk of death, stroke and heart failure
As Prognostic Item
Is useful Than
-
To Incidence rose with age, associated to ischemic heart disease, hypertension and otrher cardiac diseases. AF independently increased the risk for stroke (RR 2.07), congestive heart failure (RR 2.98) and total mortality (RR 1.31)
J Am Coll Cardiol. 2000 Jul;36(1):139-46 Randomized Controlled Trial
IN StudyID: Kuhlkamp 2000, atrial fibrillation, persistent The Use of
beta blockers, metoprolol
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects - at 6 months
Can J Cardiol. 1991 Nov;7(9):407-9 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Kyles 1991, atrial fibrillation The Use of
propafenone
As Treatment, Chronic
Is good Than
no comparison
To AF recurrence, adverse effects - at 30 months
Ann Cardiol Angeiol (Paris). 1996 Oct;45(8):469-79 Randomized Controlled Trial, Multicenter Trial
IN StudyID: Lardoux 1996, atrial fibrillation The Use of
cibenzoline
As Treatment, Chronic
Is equal Than
propafenone
To AF recurrence, adverse effects, pro-arrhythmia - at 6 months
Am Heart J. 1992 Sep;124(3):645-50 Cross-Over
IN StudyID: Lau 1992, atrial fibrillation, paroxysmal, recurrent The Use of
flecainide
As Treatment, Chronic
Is equal Than
quinidine
To AF recurrence, adverse effects - at 2 months
Arch Intern Med. 2003 Apr 14;163(7):777-85 Meta-Analysis
IN StudyID: Letelier 2003, atrial fibrillation The Use of
amiodarone
As Treatment, Acute
Is better Than
placebo
To converting AF to sinus rhythm
Minerva Cardioangiol. 1973 Oct; 21(10): 668-71 Clinical Trial
IN StudyID: Levi 1973 (subordinated publication), atrial fibrillation The Use of
quinidine
As Treatment, ?
Is - Than
practolol
To Not available
Cardiology. 1973; 58(6): 364-8 Randomized Controlled Trial
IN StudyID: Levi 1973, atrial fibrillation The Use of
quinidine plus beta-blocker (practolol)
As Treatment, Acute
Is equal Than
quinidine alone
To acute pharmacological cardioversion of AF
Circulation. 1999 Jun 15;99(23):3028-35 Cohorts
IN StudyID: Levy 1999, atrial fibrillation The Use of
natural history of AF by type and aetiology
As Prognostic Item
Is useful Than
-
To -
Am J Cardiol. 2004 Jan 1;93(1):45-8 Randomized Controlled Trial?
IN StudyID: Li 2004, atrial fibrillation, persistent The Use of
diverse AAR
As Treatment, Chronic
Is equal Than
rate control drugs
To AF recurrence - at 1 month
S Afr Med J 1984 Mar 10;65(10):367-9 Randomized Controlled Trial
IN StudyID: Lloyd 1984, atrial fibrillation The Use of
quinidine, disopyramide
As Treatment, Chronic
Is equal Than
placebo
To mortality, stroke, AF recurrence, adverse effects, pro-arrhythmia - at 6 months
Acta Med Scand. 1988;223(1):53-9 Cohorts
IN StudyID: Lundstrom 1988, atrial fibrillation, natural history, frequency of recidive The Use of
serial electrical cardioversion, not followed by antiarrhythmics
As Treatment, Acute
Is good Than
no comparison
To converted and to mantain sinus rythm: 23% at 1 year, 16% at 2 years
Cardiovasc Drugs Ther. 2003 Jan;17(1):31-39 Randomized Controlled Trial
IN StudyID: Manios 2003, atrial fibrillation, rejected The Use of
amiodarone
As Treatment, Chronic
Is better Than
diltiazem, no treatment
To AF recurrence - at 6 weeks
British Journal of Clinical Practice. Supplement. 1986 Apr;44:52-60 Controlled Trial (non-randomized)
IN StudyID: Martin 1986, atrial fibrillation, paroxysmal The Use of
amiodarone
As Treatment, Chronic
Is not available Than
disopyramide
To not available
Cardiology. 1990;77(6):443-9 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Mary-Rabine 1990, atrial fibrillation, paroxysmal, persistent, rejected The Use of
flecainide
As Treatment, Chronic
Is good Than
-
To AF recurrence, adverse effects, heart failure - at ? Months
New Trends in Arrhytmias. 1991;7(4):693-698 Cross-Over
IN StudyID: Massacci 1991, atrial fibrillation, paroxysmal, recurrent The Use of
amiodarone
As Treatment, Chronic
Is equal Than
flecainide
To AF recurrence, adverse effects - at 4 weeks
Ann Intern Med. 2003 Dec 16;139(12):1018-33 Review (Narrative)
IN StudyID: McNamara 2003, atrial fibrillation The Use of
diverse AAR, diverse interventions for cardioversion, for rate control
As Treatment, Acute
Is useful Than
placebo, or no treatment, or other drug
To control AF, or reduce stroke and other complications of AF
J Fam Pract 2000 Nov;49(11):1033-46 Meta-Analysis
IN StudyID: Miller 2000, atrial fibrillation, existing meta-analysis The Use of
diverse antiarrhythmic drugs
As -
Is better Than
placebo or rate control
To maintining sinus rhythm. Not data about mortality or adverse effects.
Japanese Pharmacology and Therapeutics. 1995;23(7):113-120 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Mizutani 1995, atrial fibrillation, paroxysmal The Use of
pilsicainide
As Treatment, Chronic
Is bad Than
no controls
To mortality, AF recurrence, adverse effects, pro-arrythmia - at 8 months
MMWR Morb Mortal Wkly Rep 2003 Feb 21;52(7):128, 130-1 Descriptive
IN StudyID: MMWR 2003, atrial fibrillation, epidemiology The Use of
mortality, AF as contributing cause of
As Prognostic Item
Is useful Than
-
To The frequency with which AF is reported on death certificates as a contributing cause of death has increased since 1980, primarily in persons aged > 75 years
Am J Cardiol. 1996 Jan 25;77(3):53A-59A Randomized Controlled Trial, Multicenter Trial
IN StudyID: Naccarelli 1996, atrial fibrillation, paroxysmal The Use of
flecainide
As Treatment, Chronic
Is better Than
quinidine
To AF recurrence, adverse effects - at 12 months
Ter Arkh. 1990; 62(9): 47-51 not available
IN StudyID: Nedostup 1990, atrial fibrillation The Use of
amiodarone
As Treatment, Chronic
Is - Than
quinidine
To not available
Eur Heart J. 2007 Jun;28(11):1351-7 Randomized Controlled Trial
IN StudyID: Nergardh 2007, atrial fibrillation The Use of
beta blockers, metoprolol, plus repeated cardioversion if needed
As Treatment, Chronic
Is better Than
placebo, plus repated cardioversion if needed
To reduce recurrence of AF at 6 months: 54% metoprolol VS 74% placebo.
Heart 2002 Jun;87(6):535-43 Meta-Analysis
IN StudyID: Nichol 2002, atrial fibrillation, existing meta-analysis The Use of
diverse antiarrhythmic drugs, grouped by classes
As Treatment, Acute
Is better Than
placebo
To converting AF to sinus rhythm. At a median follow-up of 24 hr, median proportion of patients in sinus rhythm was 55% in intv. and 32% in cont.
Am Heart J. 2000 Sep;140(3):437-44 Randomized Controlled Trial
IN StudyID: Okishige 2000, atrial fibrillation, persistent The Use of
pilsicainide
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, mortality, adverse effects - at 12 and 24 months
Clin Cardiol. 1997 Apr;20(4):337-40 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Opolski 1997, atrial fibrillation, persistent The Use of
amiodarone
As Treatment, Chronic
Is good Than
no comparison
To AF recurrence, adverse effects - at 12 months
Z Kardiol 1999 Mar;88(3):195-207 Randomized Controlled Trial
IN StudyID: PAFAC (subordinated publication), atrial fibrillation, persistent The Use of
quinidine, sotalol
As Treatment, Chronic
Is - Than
placebo
To mortality, AF recurrence - at 12 months
Eur Heart J. 2004 Aug;25(16):1385-94 Randomized Controlled Trial
IN StudyID: PAFAC, atrial fibrillation, persistent The Use of
quinidine, sotalol
As Treatment, Chronic
Is better Than
placebo
To mortality, adverse effects, pro-arrhythmia, AF recurrence - at 12 months
Am J Cardiol. 2004 Dec 1;94(11):1379-82 Cohorts
IN StudyID: Patel 2004, atrial fibrillation, mortality The Use of
natural history, mortality
As Prognostic Item
Is useful Than
-
To AF is associated with higher mortality, even when main medical condition is not cardiac
Arch Mal Coeur Vaiss. 2002 Jun;95(6):567-72 Clinical Trial (non-controlled, non-randomized)
IN StudyID: PEPS 2002, atrial fibrillation, rejected The Use of
propafenone
As Treatment, Chronic
Is useful Than
not controlled
To AF recurrence, adverse effects, pro-arrhythmia - at 12 months
Eur Heart J. 2003 Aug;24(15):1430-6 Randomized Controlled Trial
IN StudyID: PIAF 2000 (subordinated publication), atrial fibrillation, rate control strategy, functional status The Use of
rhythm control strategy (amiodarone)
As Treatment, Chronic
Is equal Than
rate control strategy (verapamil and anticoagulation)
To impact on quality of life - at 1 year
Lancet. 2000 Nov 25;356(9244):1789-94 Randomized Controlled Trial
IN StudyID: PIAF 2000, atrial fibrillation, rate control strategy The Use of
rhythm control strategy (amiodarone)
As Treatment, Acute
Is equal Than
rate control strategy (verapamil and anticoagulation)
To improvement in symptoms related to atrial fibrillation. Exercise tolerance is better with rhythm control, although hospital admission is more frequent. Only 23% patients in amiodarone were in sinus rhythm at 1 year.
Am J Cardiol. 1991 Apr 1;67(8):713-717 Randomized Controlled Trial
IN StudyID: Pietersen 1991, atrial fibrillation, paroxysmal The Use of
flecainide
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects, mortality - at 3 months
Arch Mal Coeur Vaiss. 1998 Dec;91(12):1481-6 Randomized Controlled Trial, Multicenter Trial
IN StudyID: Piot 1998, atrial fibrillation The Use of
cibenzoline
As Treatment, Chronic
Is equal Than
disopyramide
To AF recurrence, adverse effects - at 6 months
Eur Heart J. 2001 Aug;22(16):1504-10 Randomized Controlled Trial
IN StudyID: Plewan 2001, atrial fibrillation The Use of
sotalol
As Treatment, Chronic
Is equal Than
beta-blockers, bisoprolol
To AF recurrence, pro-arrhythmia - at 12 months
Am J Cardiol. 1989 Jan 1;63(1):114-6 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Porterfield 1989, atrial fibrillation, persistent The Use of
propafenone
As unknow
Is - Than
unknow
To unknow
Cardiovasc Drugs Ther. 1996 May;10(2):145-52 Randomized Controlled Trial
IN StudyID: PRODIS 1996, atrial fibrillation, persistent The Use of
propafenone
As Treatment, Chronic
Is better Than
disopyramide
To mortality, AFrecurrence, adverse effects, pro-arrhythmia - at 6 months
Circulation. 1997 Oct 7;96(7):2455-61
IN StudyID: Psaty 1997, atrial fibrillation The Use of
aetiology: associated factors causing AF. Incidence of AF
As -
Is - Than
-
To A history of valvular heart disease, coronary disease, advancing age, higher levels of systolic blood pressure, height, glucose, and left atrial size were all associated with an increased risk of AF
Circulation. 1995 Nov 1;92(9):2550-7 Randomized Controlled Trial
IN StudyID: PSVT 1995, atrial fibrillation, rejected The Use of
propafenone
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects - at ? Time
N Engl J Med. 2002 Dec 5;347(23):1834-40 Randomized Controlled Trial
IN StudyID: RACE 2002, atrial fibrillation, rate control strategy The Use of
rate control strategy (drugs and anticoagulation)
As Treatment, Chronic
Is equal Than
rhythm control strategy (electrical cardioversion and antiarrhythmics, anticoagulation recommended)
To combined events (cardiovascular death, heart failure, any embolism, bleeding, severe drug adverse effects, pacemaker): 3,44%/year in rate-c vs 4,52%/year in rhythm-c. Patients in sinus rhythm at 2,3 years were 10% in rate-c vs 39% in rhythm-c
Am J Cardiol. 2003 Oct 15;92(8):941-6 Randomized Controlled Trial
IN StudyID: RAFT 2003, atrial fibrillation The Use of
propafenone
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects - at ? Time
Acta Med Scand Suppl. 1981; 645: 23-8 Cross-Over, Randomized Controlled Trial
IN StudyID: Rasmussen 1981, atrial fibrillation, rejected The Use of
quinidine
As Treatment, Chronic
Is better Than
verapamil
To AF recurrence, adverse effects, sudden death
Am J Cardiol. 1993 Mar 1;71(7):558-63 Randomized Controlled Trial
IN StudyID: Reimold 1993, atrial fibrillation The Use of
propafenone
As Treatment, Chronic
Is equal Than
sotalol
To AF recurrence, adverse effects, mortality - at 12 months
Br Heart J 1971 Mar;33(2):220-5 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Resnekov 1971, atrial fibrillation The Use of
quinidine
As Treatment, Chronic
Is equal Than
no treatment
To avoid AF recurrence, and worse for adverse effects
Cardiologia. 1992 Feb;37(2):123-7 Randomized Controlled Trial
IN StudyID: Richiardi 1992, atrial fibrillation, paroxysmal The Use of
propafenone
As Treatment, Chronic
Is equal Than
quinidine
To AF recurrence, adverse effects - at 6 months
J Clin Epidemiol 2002 Apr;55(4):358-63 Case-Control
IN StudyID: Ruigomez 2002, atrial fibrillation, persistent The Use of
incidence
As -
Is useful Than
-
To incidence rate of chronic AF was 1.7 per 1,000 person-years, and increased markedly with age. The major risk factors were age, high BMI, excessive alcohol consumption, and prior cardiovascular comorbidity. 40% did not receive either warfarin or aspirin
Am J Cardiol. 2003 Aug 15;92(4):468-72 Randomized Controlled Trial
IN StudyID: Safe-T 2005 (subordinated publication), atrial fibrillation The Use of
amiodarone, sotalol
As Treatment, Chronic
Is - Than
placebo
To AF recurrence, a number of parameters as secondary end points - at 12 to 54 months
N Engl J Med. 2005 May 5;352(18):1861-72 Randomized Controlled Trial
IN StudyID: Safe-T 2005, atrial fibrillation, persistent The Use of
amiodarone, sotalol
As Treatment, Chronic
Is better Than
placebo
To mortality, stroke, proarrhythmia, AF recurrence - at 12 months
Circulation. 2000 Nov 7;102(19):2385-90 Randomized Controlled Trial, Multicenter Trial
IN StudyID: SAFIRE 2000, atrial fibrillation, persistent The Use of
dofetilide
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, proarrhythmia - at 12 months
Am J Cardiol. 1991 Nov 1;68(11):1227-30 Randomized Controlled Trial, Multicenter Trial
IN StudyID: Singh 1991, atrial fibrillation, persistent The Use of
sotalol
As unknow
Is - Than
unknow
To unknow
Prog Cardiovasc Dis. 2001 Sep-Oct;44(2):121-52 Meta-Analysis
IN StudyID: Slavik 2001, atrial fibrillation The Use of
IV procainamide, oral quinidine, oral flecainide, oral propafenone, IV or hight-dose oral amiodarone, IV ibutilide
As Treatment, Acute
Is better Than
placebo
To converting AF to sinus rhythm
Circ J. 2002 Jun;66(6):553-6 Randomized Controlled Trial, Multicenter Trial
IN StudyID: SMART 2002, atrial fibrillation The Use of
aprindine
As Treatment, Chronic
Is equal Than
digoxin, placebo
To AF recurrence, adverse effects - at 6 months
Arq Bras Cardiol 1998 Jan;70(1):43-9 Randomized Controlled Trial, Multicenter Trial
IN StudyID: SOCESP 1999 (subordinate publication), atrial fibrillation The Use of
sotalol
As Treatment, Chronic
Is equal Than
quinidine
To AF recurrence, pro-arrhythmia - at 6 months
Am J Cardiol. 1999 Nov 1;84(9):1033-7 Randomized Controlled Trial, Multicenter Trial
IN StudyID: SOCESP 1999, atrial fibrillation The Use of
sotalol
As Treatment, Chronic
Is equal Than
quinidine
To AF recurrence, pro-arrhythmia - at 6 months
Br Heart J 1975 May;37(5):486-92 Randomized Controlled Trial
IN StudyID: Sodermark 1975, atrial fibrillation The Use of
quinidine
As Treatment, Chronic
Is better Than
no treatment
To AF recurrence, adverse effects - at 12 months
Z Kardiol (Zeitschrift fur Kardiologie) 1999 Mar;88(3):185-94 Randomized Controlled Trial
IN StudyID: SOPAT (subordinated publication), atrial fibrillation, paroxysmal The Use of
quinidine, sotalol
As Treatment, Chronic
Is - Than
placebo
To at 12 months: AF recurrence, adverse effects, pro-arrhythmia, mortality
Eur Heart J. 2004 Aug;25(16):1395-404 Randomized Controlled Trial
IN StudyID: SOPAT, atrial fibrillation, paroxysmal The Use of
quinidine, sotalol
As Treatment, Chronic
Is better Than
placebo
To at 12 months: AF recurrence, adverse effects, pro-arrhythmia, mortality
Am J Cardiol. 1999 Jun 15;83(12):1629-32 Meta-Analysis
IN StudyID: Southworth, existing meta-abalysis, atrial fibrillation The Use of
sotalol
As Treatment, Chronic
Is equal Than
quinidine
To maintaining sinus rhythm at 6 months, and both agents are superior to control. There is a trend for both agents to increase mortality
J Am Coll Cardiol. 2003 May 21;41(10):1690-6 Randomized Controlled Trial
IN StudyID: STAF 2003, atrial fibrillation, rate control strategy The Use of
rate control strategy (pharmacologic or invasive rate-control and anticoagulation)
As Treatment, Chronic
Is equal Than
rhythm control strategy (restoration and maintenance of sinus rhythm)
To combined major cardiovascular events (death, heart arrest, stroke, and systemic embolism): 6.09%/year in rate-c vs 5.54%/year in rhythm-c. Patients in sinus rhythm at 3 years were 0% in rate-c vs 23% in rhythm-c
Heart. Aug 1999; 82(2):170-5 Cross-Over, Randomized Controlled Trial
IN StudyID: Steeds 1999, atrial fibrillation, paroxysmal The Use of
sotalol
As Treatment, Chronic
Is equal Than
atenolol
To at 1 month: AF recurrence, adverse effects
Dtsch Med Wochenschr. 1988 Dec 2;113(48):1867-71 Randomized Controlled Trial
IN StudyID: Steinbeck 1988, atrial fibrillation, paroxysmal The Use of
flecainide, quinidine
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse affects - at 11 months
Am J Med. 2002 Oct 1;113(5):359-64 Cohorts
IN StudyID: Stewart 2002, atrial fibrillation The Use of
associated risks
As Prognostic Item
Is useful Than
0
To Atrial fibrillation is independently associated with an increased long-term risk of stroke, heart failure, and all-cause mortality
Am J Cardiol. 1997 Feb 15;79(4):418-23 Randomized Controlled Trial, Multicenter Trial
IN StudyID: Stroobandt 1997, atrial fibrillation, persistent The Use of
propafenone
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects - at 6 months
J Cardiovasc Electrophysiol. 2008 Feb;19(2):172-7 Randomized Controlled Trial
IN StudyID: SVA-4, atrial fibrillation The Use of
azimilide
As Treatment, Chronic
Is equal Than
placebo
To modify, at 6 months, mortality or Af recurrence, while increasing adverse effects and pro-arrhythmia
Eur Heart J. 2005 Oct;26(19):2000-6. Epub 2005 May 4 Meta-Analysis
IN StudyID: Testa 2005, atrial fibrillation, rate control strategy The Use of
rate control strategy
As Treatment, Chronic
Is better Than
rhythm control strategy
To reduce a combined endpoint of all cause death and thromboembolic stroke (OR 0.84 (0.73, 0.98)). No difference in all-cause death, systemic embolism and major bleeding.
Br J Clin Pract Suppl. 1986 Apr;44:42-8 Cross-Over
IN StudyID: Tonet 1986, atrial fibrillation The Use of
amiodarone
As Treatment, Chronic
Is unknown Than
quinidine
To unknown
Ann Cardiol Angeiol (Paris). 1995 Nov;44(9):525-31 Randomized Controlled Trial
IN StudyID: Touboul 1996, atrial fibrillation The Use of
cibenzoline
As Treatment, Chronic
Is equal Than
quinidine
To AF recurrence, adverse effects, pro-arrhythmia - at 6 months
Circulation (Supp) 1988;78(4):ii626 Randomized Controlled Trial
IN StudyID: Van Gelder 1989 (subordinated publication), atrial fibrillation, persistent The Use of
flecainide
As Treatment, Chronic
Is better Than
placebo
To not available
Am J Cardiol. 1989 Dec 1;64(19):1317-21 Randomized Controlled Trial
IN StudyID: Van Gelder 1989, atrial fibrillation, persistent The Use of
flecainide
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects, proarrhythmia - at ? time
Arch Intern Med. 1996 Dec 9-23;156(22):2585-92 Cohorts
IN StudyID: Van Gelder 1996, atrial fibrillation, natural history, frequency of recidive The Use of
serial electrical cardioversion, not followed by antiarrhythmics
As Treatment, Chronic
Is bad Than
no control
To maintain sinus rhythm: 42% and 27% of patients after 1 and 4 years, respectively
J Cardiovasc Pharmacol. 1989 Jan;13(1):32-6 Cross-Over
IN StudyID: Van Wijk 1989, atrial fibrillation, paroxysmal, recurrent The Use of
flecainide
As Treatment, Chronic
Is better Than
quinidine
To AF recurrence, adverse effects - at 3 months
Eur Heart J. 2003 Aug;24(15):1425-9 Randomized Controlled Trial, Multicenter Trial
IN StudyID: VERARAF 2003, atrial fibrillation, persistent The Use of
amiodarone, flecainide, verapamil
As Treatment, Chronic
Is equal Than
flecainide, verapamil addition to any of both
To AF recurrence - at 3? Month
Ital Heart J 2001 Mar;2(3 Suppl):322-3 Randomized Controlled Trial
IN StudyID: Vergara 2001 (get full text), atrial fibrillation The Use of
dofetilide
As Treatment, Chronic
Is - Than
Not available
To Not available
Circulation. 2003 Jun 17;107(23):2926-31 Randomized Controlled Trial
IN StudyID: Vermes 2003, atrial fibrillation, heart failure The Use of
angiotensing converting enzyme inhibitors, enalapril
As Treatment, Chronic
Is better Than
placebo
To reducing the risk of development of atrial fibrillation in patients with left ventricular dysfunction (at 3 years: 5,4% ACEi vs 24% placebo)
Clin Ter. 1992 Jan; 140(1 Pt 2): 35-9 Randomized Controlled Trial
IN StudyID: Villani 1992, atrial fibrillation The Use of
amiodarone
As Treatment, Chronic
Is better Than
disopyramide
To AF recurrence, adverse effects - at 12 months
Acta Cardiologica. 1981;36(6):431-44 Clinical Trial
IN StudyID: Vitolo 1981, atrial fibrillation The Use of
amiodarone
As Treatment, Chronic
Is not available Than
quinidine
To not available
Arch Intern Med. 2003 Apr 28;163(8):936-43 Meta-Analysis
IN StudyID: Walraven 2003, atrial fibrillation The Use of
risk factors for stroke: several clinical items: previous stroke or TIA, hypertension, symptomatic coronary artery disease, and diabetes
As Prognostic Item
Is useful Than
-
To predicting risk of stroke: patients with AF and none of these 4 clinical features and who take aspirin have stroke rates comparable to those of age-matched community cohorts (1.2 events per 100 PYs) Age > 75 years was not predictive
Am Heart J. 1997 Apr;133(4):441-6 Randomized Controlled Trial
IN StudyID: Wanless 1997, atrial fibrillation, paroxysmal The Use of
sotalol
As Treatment, Chronic
Is better Than
placebo
To time to arrhythmia/AF recurrence, adverse effects - at ? time
Circulation. 2003 Aug 12;108(6):711-6 Descriptive
IN StudyID: Wattigney 2003, atrial fibrillation, epidemiology The Use of
atrial fibrillation, as contributing cause of hospitalization
As Prognostic Item
Is useful Than
no comparison here
To Hospitalizations for atrial fibrillation have increased dramatically (2- to 3-fold) in recent years
Arch Intern Med 1995 Sep 25;155(17):1885-91 Meta-Analysis
IN StudyID: Zarembski, atrial fibrillation, existing meta-analysis The Use of
amiodarone
As Treatment, Chronic
Is equal Than
flecainide
To maintenance of sinus rhythm.
Z Kardiol. 1994;83(Suppl 5):101-8 Randomized Controlled Trial
IN StudyID: Zehender 1992 (subordinated publication), atrial fibrillation, persistent The Use of
amiodarone
As Treatment, Acute
Is equal Than
quinidine + verapamil
To acute conversion of chronic AF
J Am Coll Cardiol. 1992 Apr;19(5):1054-9 Randomized Controlled Trial
IN StudyID: Zehender 1992, atrial fibrillation, persistent The Use of
amiodarone
As Treatment, Chronic
Is equal Than
quinidine + verapamil
To acute conversion of chronic AF